04/24
Headlines

RGEN

NASDAQ Recent Insider Buying: Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Equinix Inc (NASDAQ:EQIX), AspenBio Pharma (NASDAQ:APPY)

Colin Pettis02 mins

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Kovner Bruce purchased 1,250,000 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $5,012,500.00. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 1.01% in last session and finished the day…

Read More

Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

John Bellich02 mins

Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -2.62% in last session and finished the day…

Read More
Gilead Sciences GILD NASDAQ:GILD

Biotech Bullish Stocks: Regulus Therapeutics Inc (NASDAQ:RGLS), Insys Therapeutics (NASDAQ:INSY), Repligen Corporation (NASDAQ:RGEN), Sarepta Therapeutics (NASDAQ:SRPT)

Kevin Long02 mins

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) were the target of a significant decrease in short interest in January. As of March 14th, there was short interest totaling 1,460,571 shares, a decrease of 20.3% from the February 28th total of 1,832,140 shares, Analyst Ratings Newsreports. Regulus Therapeutics Inc (NASDAQ:RGLS) stock performance was 5.09% in last session…

Read More

Stock Runners: Repligen (NASDAQ:RGEN), Durata Therapeutics (NASDAQ:DRTX), Acadia Realty Trust (NYSE:AKR), International Game Technology (NYSE:IGT), DDR Corp. (NYSE:DDR)

Chris Lewis03 mins

Repligen Corp. (NASDAQ:RGEN) released its earnings data on Monday, 11 Aug 2014. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior…

Read More

Trader’s Recap – Johnson & Johnson (NYSE:JNJ) , Twitter (NYSE:TWTR) , PRAA, Repligen (NASDAQ:RGEN) , Lincoln Educational Services (NASDAQ:LINC)

Chris Lewis03 mins

Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company’s common stock. Repurchases may be made at management’s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be…

Read More

Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Richard Atkins02 mins

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation…

Read More